UBS analyst David Dai raised the firm’s price target on Iovance Biotherapeutics (IOVA) to $4 from $2 and keeps a Neutral rating on the shares. Fundamentals improved in Q4, but Amtagvi acceleration remains uncertain, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IOVA:
- Iovance Biotherapeutics Signals Strong Momentum In Earnings
- Iovance Biotherapeutics price target raised to $4 from $3 at Baird
- Iovance Biotherapeutics price target raised to $11 from $10 at Barclays
- Iovance upgraded to Outperform from Market Perform at Citizens
- Iovance Biotherapeutics price target lowered to $16 from $17 at Chardan